Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers

Phase 1

Completed

• Conditions: Healthy Volunteers
• Interventions: Drug: REGN2222(SAR438584); Drug: placebo

• Registration Number: NCT02121080
• Lead Sponsor: Regeneron Pharmaceuticals

Brief Summary

This is a phase 1, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetic (PK) profile, and immunogenicity of REGN2222 ascending in cohorts of healthy adult volunteers.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-04-21
• Study First Submitted QC: 2014-04-21
• Study First Posted: 2014-04-23
• Study Start: 2014-05
• Primary Completion: 2015-02
• Study Completion: 2015-02
• Status Verified: 2015-03
• Last Update Submitted: 2015-03-10
• Last Update Posted: 2015-03-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 132

Inclusion Criteria

1. A healthy man or woman aged 18 to 60 years
2. Body mass index between 18.0 kg/m2 and 32.0 kg/m2, inclusive
3. Willing and able to comply with clinic visits and study-related procedures
4. Provide signed informed consent

Exclusion Criteria

1. Serum hemoglobin, creatinine, alkaline phosphatase, CPK, and/or hepatic enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT], total bilirubin [unless the investigator has evidence that increased bilirubin corresponds to a Gilbert's type syndrome with elevated indirect bilirubin]) that is >1.5 the upper limit of normal (ULN), or any laboratory findings showing evidence of organ dysfunction or any clinically significant abnormalities from the normal range, as determined by the investigator at the screening visit

2. Use of any concomitant medications within 30 days or at least 5 half-lives, whichever is longer, of the screening visit, including prescription medications (except contraceptives), nutritional supplements, and over-the-counter medications (except acetaminophen)

3. Hospitalization for any reason within 60 days of the screening visit

4. History of or positive human immunodeficiency virus (HIV) screen result at the screening visit

5. History of or positive blood test result for hepatitis B surface antigen and/or hepatitis C virus antibody at the screening visit

6. History of autoimmune disease

7. History of respiratory disease (e.g, asthma, chronic obstructive pulmonary disease)

8. History of drug or alcohol abuse within 1 year prior to the screening visit

9. Participation in any clinical research study evaluating another investigational drug or therapy within 30 days, or within at least 5 half-lives, of the investigational drug (whichever is longer) prior to the screening visit

10. Pregnant or breastfeeding woman

11. Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception during the study, and up to 3 months after the last dose of the study drug (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly)

    • Contraception is not required for men with documented vasectomy. **Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of childbearing potential. Contraception is not required for women with documented hysterectomy or tubal ligation.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort 3	REGN2222(SAR438584)	Dosing regimen 3
Cohort 4	REGN2222(SAR438584)	Dosing regimen 4
Cohort 5	placebo	Dosing regimen 5
Cohort 2	REGN2222(SAR438584)	Dosing regimen 2
Cohort 3	placebo	Dosing regimen 3
Cohort 4	placebo	Dosing regimen 4
Cohort 2	placebo	Dosing regimen 2
Cohort 1	REGN2222(SAR438584)	Dosing regimen 1
Cohort 1	placebo	Dosing regimen 1
Cohort 5	REGN2222(SAR438584)	Dosing regimen 5

Primary Outcome Measures

Name	Time	Method
The incidence and severity of treatment-emergent adverse events (TEAEs) in participants treated with REGN2222 or placebo.	from day 1 up to week 20 (EOS)

Secondary Outcome Measures

Name	Time	Method
Serum concentration	from day 1 over time up to week 20	Serum concentration of REGN2222 over time up to week 20
Presence or absence of antibodies	from day 1 over time up to week 20	The presence or absence of antibodies against REGN2222 over time up to week 20